Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JLP-2302 and JP-1366 in Healthy Volunteers
NCT07181538Phase 1Completed
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Feb 2025
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zastaprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Onconic Therapeutics Inc. Primary endpoints: Area under the plasma drug concentration-time curve from time zero to the last measurable concentration and Peak Plasma Concentration. Started Feb 2025; status: completed.
02
Drugs
zastaprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07181538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181538.